Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNP-019
- Development stage
- Preclinical
- Lead developer
- KumhoHT
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
DNP-019 is an investigational **monoclonal antibody** developed by **DiNonA** as a potential therapeutic for **COVID-19**. Publicly available information indicates it was advanced as a SARS-CoV-2 antibody program and that **Samsung Biologics** entered a development and manufacturing collaboration to support cell line, process development, and production activities. Specific target, epitope, and detailed mechanism of action have not been clearly disclosed in reliable public sources, so it is best characterized as an early-stage antiviral antibody candidate for coronavirus infection.
Beyond the preview
Go deeper on DNP-019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNP-019.